The American Medical Association (AMA) has expressed concerns about the use of botanical drugs, including marijuana and kratom, citing the need for rigorous scientific testing and evidence-based standards to ensure their safety and efficacy. The organization has urged federal officials to uphold “known and widely accepted scientific and clinical standards” for testing and approval of these substances, rather than allowing political or commercial interests to influence the process.
The AMA has specifically called for the development of a “special schedule” to support research on marijuana’s potential medical utility, and has emphasized the importance of conducting high-quality clinical trials and post-market safety monitoring. The organization has also expressed concerns about the lack of standardization in the production and marketing of botanical drugs, which can lead to a dangerous and unregulated marketplace.
The AMA’s concerns were outlined in a letter to the Food and Drug Administration (FDA) in response to a request for information about botanical drug products. The letter was signed by AMA President Willie Underwood III, who emphasized the need for a science-based approach to the regulation of botanical drugs.
“We need science, not social media hype, to determine what belongs in our medicine cabinets,” Underwood said. “Calling something ‘natural’ doesn’t make it safe. We must prioritize the safety and well-being of our patients and the public, and ensure that any new treatments or products are thoroughly tested and proven effective before they are approved for use.”
The AMA’s stance on botanical drugs is part of a broader effort to promote evidence-based medicine and to reduce the risks associated with unregulated substances. The organization has been a vocal advocate for the need for rigorous scientific testing and evidence-based standards in the development and approval of new treatments and products, and has called for greater transparency and accountability in the pharmaceutical industry.
In recent years, the AMA has taken a number of positions on drug policy issues, including opposing commercial marijuana legalization, supporting the expungement of cannabis records, and advocating for broad drug decriminalization. The organization has also called for greater research into the potential therapeutic benefits of marijuana and other substances, and has emphasized the need for a balanced and evidence-based approach to drug policy.
